Cargando…

The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study

BACKGROUND: World Health Organization (WHO) has recommended individuals with increased risk of contracting influenza A H5N1 infection to be immunized against the virus during the inter-pandemic period. Safety and immunogenicity of H5N1 vaccine among participants primed with homologous or heterologou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Sung-Hsi, Liu, Ming-Tsan, Tsai, Yao-Chou, Liao, Chung-Hsin, Chen, Chih-Ming, Wang, Wei-Yao, Huang, Yi-Lung, Chang, Feng-Yee, Chou, Pesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236496/ https://www.ncbi.nlm.nih.gov/pubmed/25394941 http://dx.doi.org/10.1186/s12879-014-0587-z

Ejemplares similares

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

Heterologous Prime-Boost Vaccination with MF59-Adjuvanted H5 Vaccines Promotes Antibody Affinity Maturation towards the Hemagglutinin HA1 Domain and Broad H5N1 Cross-Clade Neutralization
por: Khurana, Surender, et al.
Publicado: (2014)

Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults
por: Frey, Sharon S., et al.
Publicado: (2023)

Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells
por: Tzeng, Tsai-Teng, et al.
Publicado: (2020)

Effect of Influenza A(H5N1) Vaccine Prepandemic Priming on CD4(+) T-Cell Responses
por: Nayak, Jennifer L., et al.
Publicado: (2015)

Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans
por: Levine, Min Z, et al.
Publicado: (2017)

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
por: Gillard, Paul, et al.
Publicado: (2012)

MF59(®)-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
por: Banzhoff, Angelika, et al.
Publicado: (2009)

Correction: MF59(®)-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
por: Banzhoff, Angelika, et al.
Publicado: (2009)

Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
por: Wijnans, Leonoor, et al.
Publicado: (2013)

Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
por: Ou, Huilin, et al.
Publicado: (2017)

Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial
por: Mulligan, Mark J., et al.
Publicado: (2014)

Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine
por: Ou, Huilin, et al.
Publicado: (2016)

Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study
por: Rubinstein, F, et al.
Publicado: (2013)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly
por: Frey, Sharon E, et al.
Publicado: (2019)

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
por: Villa, Marco, et al.
Publicado: (2013)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
por: Banzhoff, Angelika, et al.
Publicado: (2008)

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
por: Nagai, Hideaki, et al.
Publicado: (2010)

Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1
por: Vela, Eric M., et al.
Publicado: (2011)

H5N1 Viruses and Vaccines
por: Subbarao, Kanta, et al.
Publicado: (2007)

Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age
por: Nolan, Terry, et al.
Publicado: (2014)

Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza
por: Vodeiko, Galina M., et al.
Publicado: (2011)

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children
por: Kazmin, Dmitri, et al.
Publicado: (2023)

Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine
por: Rudenko, Larisa, et al.
Publicado: (2015)

Long‐term vaccine‐induced heterologous protection against H5N1 influenza viruses in the ferret model
por: Ducatez, Mariette F., et al.
Publicado: (2012)

Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study
por: Steens, Anneke, et al.
Publicado: (2011)

Heterologous Humoral Response against H5N1, H7N3, and H9N2 Avian Influenza Viruses after Seasonal Vaccination in a European Elderly Population
por: Sanz, Ivan, et al.
Publicado: (2017)

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
por: Levine, Min Z., et al.
Publicado: (2019)

Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products
por: Lai, Chia-Chun, et al.
Publicado: (2020)

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008)

Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains
por: Camilloni, Barbara, et al.
Publicado: (2014)

A VLP Vaccine Induces Broad-Spectrum Cross-Protective Antibody Immunity against H5N1 and H1N1 Subtypes of Influenza A Virus
por: Wu, Chia-Ying, et al.
Publicado: (2012)

Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine
por: de Vries, Rory D., et al.
Publicado: (2015)

Broadening the H5N3 Vaccine Immunogenicity against H5N1 Virus by Modification of Neutralizing Epitopes
por: Rajesh Kumar, Subaschandrabose, et al.
Publicado: (2017)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

Heterologous prime-boost H1N1 vaccination exacerbates disease following challenge with a mismatched H1N2 influenza virus in the swine model
por: Pliasas, Vasilis C., et al.
Publicado: (2023)

Superior Neutralizing Antibody Response and Protection in Mice Vaccinated with Heterologous DNA Prime and Virus Like Particle Boost against HPAI H5N1 Virus
por: Ding, Heng, et al.
Publicado: (2011)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_alg94d92u1tbl5nuhmikkbp4ki